Santafe News Online

DelveInsight’s “Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

Discover Key Insights into the Geographic Atrophy Market with DelveInsight’s In-Depth Report @ Geographic Atrophy Market Size

 

Key Takeaways from the Geographic Atrophy Market Report

• The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023.
• Among the 7MM, the US accounted for the highest prevalent cases of Geographic Atrophy in 2023 while Japan accounted for the least number of prevalent cases.
• Amongst EU4 and the UK, the highest number of cases comprised from France and Germany, with France having slightly more cases than Germany.
• In 2023, the geographical atrophy accounted for nearly 955,900 cases in EU4 and the UK.
• According to the estimates, in Japan, it is observed that age-specific cases of Geographic Atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023.
• The leading Geographic Atrophy Companies such as Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.
• Promising Geographic Atrophy Pipeline Therapies such as AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, CPCB-RPE1, APL-2, IONIS-FB-LRx, ASP7317, GT005, and others.

 

Stay ahead in the Geographic Atrophy Therapeutics Market with DelveInsight’s Strategic Report @ Geographic Atrophy Market Outlook

  

Geographic Atrophy Epidemiology Segmentation in the 7MM

• Total Geographic Atrophy Prevalent Cases
• Geographic Atrophy Late Stage-specific Prevalent Cases
• Total Geographic Atrophy Diagnosed Prevalent Cases
• Geographic Atrophy Age-specific Cases
• Geographic Atrophy Cases by Visual Impairment

 

Download the report to understand which factors are driving Geographic Atrophy Epidemiology trends @ Geographic Atrophy Prevalence

 

Marketed Geographic Atrophy Drugs

 

• IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio

IZERVAY, also known as avacincaptad pegol is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. By inhibiting the formation of complement system terminal fragments, IZERVAY may decrease the activation of inflammasomes and the formation of membrane attack complexes (MAC), which occur at the end of the complement cascade. In August 2023, the US FDA approved IZERVAY for the treatment of Geographic Atrophy secondary to AMD. Concurrently, Astellas Pharma announced that the European Medicines Agency (EMA) has accepted Iveric Bio’s MAA for avacincaptad pegol for the treatment of Geographic Atrophy secondary to AMD.

 

• SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals

SYFOVRE is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. The company is evaluating pegcetacoplan in several clinical studies, including paroxysmal nocturnal hemoglobinuria (PNH), Geographic Atrophy (GA), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), complement-dependent nephropathies (CDN). SYFOVRE is the first and only approved therapy for Geographic Atrophy secondary to AMD. In January 2024, the CHMP of the EMA adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of Geographic Atrophy secondary to AMD.

 

Emerging Geographic Atrophy Drugs

 

• Tinlarebant (LBS-008): Belite Bio

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA, or advanced dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. A 2-year global Phase III PHOENIX trial is ongoing. PHOENIX is a multicenter, randomized, double-masked, placebo-controlled study to evaluate the safety and efficacy of Tinlarebant in Geographic Atrophy subjects. In November 2023, Belite Bio announced the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (UK) for the Phase III clinical trial of Tinlarebant in Geographic Atrophy or the PHOENIX study.

 

• Gildeuretinol (ALK-001): Alkeus Pharmaceuticals

Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA. According to the company’s recent presentation, a Phase III study of gildeuretinol in 200 patients with Geographic Atrophy secondary to AMD has recently been completed and is expected to read out topline data in 2024.

 

Geographic Atrophy Market Outlook

Geographic Atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward Geographic Atrophy.

 

To know more about Geographic Atrophy treatment guidelines, visit @ Geographic Atrophy Treatment Market Landscape

 

Geographic Atrophy Drugs Uptake

• IZERVAY, developed by Astellas Pharma/Iveric Bio is designed to target and inhibit complement factor C5. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. In August 2023, the US FDA approved IZERVAY for the treatment of geographic atrophy secondary to AMD.
• SYFOVRE, developed by Apellis Pharmaceuticals is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. In February 2023, the US FDA approved SYFOVRE for the treatment of geographic atrophy secondary to AMD.

 

Geographic Atrophy Market Dynamics

The Geographic Atrophy market dynamics are expected to change in the coming years. Payers’ willingness to pay is assumed to be strong since the unavailability of approved medicines creates a high unmet demand and the possibility of avoiding progression to wet AMD, which is associated with high treatment costs. Moreover, due to the existing absence of competitive therapies, clinical outcome requirements may be minimal; hence, sham or placebo-controlled clinical trials may suffice for initial entrants. Furthermore, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the geographic atrophy market in the 7MM.

 

Major Geographic Atrophy Companies

Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.

 

Learn more about the FDA-approved drugs for Geographic Atrophy @ Drugs for Geographic Atrophy Treatment

 

Scope of the Geographic Atrophy Market Report

• Coverage- 7MM
• Geographic Atrophy Companies- Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.
• Geographic Atrophy Therapies- AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, CPCB-RPE1, APL-2, IONIS-FB-LRx, ASP7317, GT005, and others.
• Geographic Atrophy Market Dynamics: Geographic Atrophy Market Drivers and Barriers
• Geographic Atrophy Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Table of Content

1. Key Insights

2. Geographic Atrophy Executive Summary

3. Competitive Intelligence Analysis for Geographic Atrophy

4. Geographic Atrophy: Market Overview at a Glance

5. Geographic Atrophy: Disease Background and Overview

6. Geographic Atrophy Patient Journey

7. Geographic Atrophy Epidemiology and Patient Population

8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Geographic Atrophy Unmet Needs

10. Key Endpoints of Geographic Atrophy Treatment

11. Geographic Atrophy Marketed Products

12. Geographic Atrophy Emerging Therapies

13. Geographic Atrophy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Geographic Atrophy Market Outlook

16. Geographic Atrophy Market Access and Reimbursement Overview

17. Geographic Atrophy KOL Views

18. Geographic Atrophy Market Drivers

19. Geographic Atrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage